Stay updated on Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedNo changes were reported in the provided changes data; the page content remains as published.SummaryDifference0.1%

- Check21 days agoChange DetectedRevision: v3.6.5 has been added, replacing the previous v3.6.4. This indicates a new revision of the page, without changes to the substantive study content.SummaryDifference0.0%

- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe page's revision tag was updated from v3.6.3 to v3.6.4, indicating a newer build of the page. This change is a backend/version update and does not modify the study details or user-visible content.SummaryDifference0.0%

- Check57 days agoChange DetectedRevision label updated from v3.6.2 to v3.6.3. This reflects a minor update to the page's versioning, not a change to visible content.SummaryDifference0.1%

- Check64 days agoChange DetectedA new revision tag Revision: v3.6.2 was added, replacing the previous v3.6.0 tag.SummaryDifference0.0%

- Check71 days agoChange DetectedPublications section added with a PubMed-cited article related to the study, and a note that such publications are automatically populated from PubMed.SummaryDifference0.2%

Stay in the know with updates to Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.